




RealRate

MEDICINAL PRODUCTS 2018

Celldex Therapeutics Inc. Rank 19 of 49





RealRate

MEDICINAL PRODUCTS 2018

Celldex Therapeutics Inc. Rank 19 of 49



The relative strengths and weaknesses of Celldex Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Celldex Therapeutics Inc. compared to the market average is the variable Goodwill, increasing the Economic Capital Ratio by 57% points. The greatest weakness of Celldex Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 55%, being 76% points above the market average of -22%.

Input Variable	Value in 1000 USD
Assets, Current	144,756
Assets, Non-Current	1,929
General and Administrative Expense	25,003
Goodwill	158,567
Liabilities, Current	27,736
Liabilities, Non-Current	51,519
Other Assets	0
Other Compr. Net Income	23
Other Expenses	-11,186
Other Liabilities	0
Other Net Income	0
Other Revenues	16,957
Property, Plant and Equipment, Net	10,372
Research and Development	96,171

Output Variable	Value in 1000 USD
Liabilities	79,255
Assets	315,624
Expenses	109,988
Revenues	16,957
Stockholders Equity	236,369
Net Income	-93,031
Comprehensive Net Income	-93,020
Economic Capital Ratio	55%